Table S1 Proportion of xenografted AR42J tumours showing relapse or senescence at end of study

Treatment outcomes	**Vehicle (n=13)**	**[^{177}Lu]Lu - DOTATATE 15 MBq (n=18)**	**[^{177}Lu]Lu - DOTATATE 30 MBq (N=18)**	**[^{177}Lu]Lu -satoreotide tetraxetan 15 MBq (N=13)**
Mice with complete tumour relapse	13/13 (100)	11/15 (73)	7/15 (47)	1/10 (10)
Mice with tumour relapse and senescent tumour lobules	0/13 (0)	4/15 (27)	6/15 (40)	7/10 (70)
Mice with complete tumour senescence	0/13 (0)	0/15 (0)	2/15 (13)	2/10 (20)

Data are expressed as n/N (%).

Table S2. Radioactivity uptake of ^{177}Lu-DOTATATE and ^{177}Lu-satoreotide tetraxetan in different organs at 96 hours post-administration of last treatment, and its relationship with SST2 expression level

Treatments	Tumour	Kidneys	Adrenals	Femur	Spleen	Tail
SST2 expression level determined by IHC	High	None	Moderate	Minimal	Minimal	None
[^{177}Lu]Lu-DOTATATE 15 MBq	1.0 (0.30)	0.066 (0.012)	0.11 (0.015)	0.006 (0.00051)	0.0032 (0.00026)	0.01 (0.0022)
[^{177}Lu]Lu-DOTATATE 30 MBq	2.2 (0.22)	0.20 (0.043)	0.23 (0.018)	0.008 (0.00043)	0.006 (0.00057)	0.016 (0.0037)
[^{177}Lu]Lu-satoreotide tetraxetan 15 MBq	3.5 (0.14)	0.51 (0.077)	0.12 (0.061)	0.014 (0.0014)	0.013 (0.0013)	0.015 (0.0014)

Data are expressed as mean (standard error of the mean) in MBq/g of tissue. IHC, immunohistochemistry; SST2, somatostatin receptor subtype 2.

Table S3. Mean haematological parameters at 96 hours post-administration and at the end of study of ^{177}Lu-DOTATATE and ^{177}Lu-satoreotide tetraxetan, in comparison to the vehicle control group

	RBC (10^3/mm^3)	**Ht (%)**	**Hb (g/dL)**	**Platelets (10^3/mm^3)**	**WBC (10^3/mm^3)**	**Lymphocytes (10^3/mm^3)**	**Neutrophils (10^3/mm^3)**
At 96 hours post-administration of last treatment							
Vehicle							
Mean	7.7	40	12	288	3.1	1.9	1.0
[^{177}Lu]Lu-DOTATATE 15 MBq							
Mean	8.0	43	12	283	2.1	1.2	0.77
Percentage of variation	3.2	6.4	-1.4	-2.0	-32	-37	-26
[^{177}Lu]Lu-DOTATATE 30 MBq							
Mean	8.4	46	13	292	2.6	1.3	1.1
Percentage of variation	9.0	14	5.0	1.3	-16	-29	2.6
[^{177}Lu]Lu-satoreotide tetraxetan 15 MBq							
Mean	8.5	51	13	258	2.2	1.0	1.0
Percentage of variation	11	25	12	-11	-29	-44	-8.7
End of study							
Vehicle							
Mean	7.3	39	11	282	2.5	1.2	1.1
[^{177}Lu]Lu-DOTATATE 15 MBq							
Mean	7.3	40	11	352	4.1	2.8	1.1
Percentage of variation	-0.6	5.2	-1.9	25	64	129	3.3
[^{177}Lu]Lu-DOTATATE 30 MBq							
Mean	7.5	38	11	400	3.9	2.3	1.3
Percentage of variation	1.8	-0.7	-2.4	42	56	95	20
[^{177}Lu]Lu-satoreotide tetraxetan 15 MBq							
Mean	8.4	43	13	347	5.3	3.9	1.2
Percentage of variation	14	12	14	23	113	229	4.9

Percentage of variation compared to the vehicle control group. Hb, haemoglobin; Ht, haematocrit; RBC, red blood cell count; WBC, white blood cell count.

Table S4. Treatment-related microscopic observations at 96 hours post-administration of last treatment and at the end of study

Treatments	Vehicle	[^{177}Lu]Lu - DOTATATE 15 MBq	[^{177}Lu]Lu - DOTATATE 30 MBq	[^{177}Lu]Lu - satoreotide tetraxetan 15 MBq
At 96 hours post-administration of last treatment				
Number of examined mice	3	3	3	3
Bone marrow				
Myeloid/erythroid ratio	**3**	**3**	**3**	**3**
Moderate increase	1	2	3	3
Mild increase	2	1	-	-
Mean score*	***2.3***	***2.7***	***3.0***	***3.0***
Spleen				
Extramedullary haematopoiesis	**3**	**3**	**3**	**3**
Marked decrease	2	-	-	-
Moderate decrease	1	2	1	1
Mild decrease	-	1	2	2
Mean score*	***3.7***	***2.7***	***2.3***	***2.3***
Kidneys				
Basophilic tubules	**0**	**2**	**1**	**1**
Minimal	-	2	1	1
End of study				
Number of examined mice	10	11	11	7
Bone marrow				
Myeloid/erythroid ratio	**9**	**11**	**11**	**7**
Moderate increase	-	1	3	6
Mild increase	3	6	6	-
Minimal increase	6	4	2	1
Mean score*	***1.2***	***1.7***	***2.1***	***2.7***
Eosinophilic vacuolated cells	**0**	**0**	**1**	**1**
Mild	-	-	1	-
Minimal	-	-	-	1

*Mean score is Σ number of animals x severity score / number of examined animals in the group.

Figure S1




Figure S1. Individual Tumour growth over time of Vehicle, [^{177}Lu]Lu -DOTATATE at 15 and 30 MBq and [^{177}Lu]Lu -satoreotide tetraxetan at 15 MBq